Cyclic Nucleotide Phosphodiesterases: important signaling modulators and therapeutic targets
Open accessThe DOI matches its Crossref record; 261 of the 261 references it cites were found in a registry or an index.
Abstract
By catalyzing hydrolysis of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), cyclic nucleotide phosphodiesterases are critical regulators of their intracellular concentrations and their biological effects. As these intracellular second messengers control many cellular homeostatic processes, dysregulation of their signals and signaling pathways initiate or modulate pathophysiological pathways related to various disease states, including erectile dysfunction, pulmonary hypertension, acute refractory cardiac failure, intermittent claudication, chronic obstructive pulmonary disease, and psoriasis. Alterations in expression of PDEs and PDE‐gene mutations (especially mutations in PDE6, PDE8B, PDE11A, and PDE4) have been implicated in various diseases and cancer pathologies. PDEs also play important role in formation and function of multimolecular signaling/regulatory complexes, called signalosomes. At specific intracellular locations, individual PDEs, together with pathway‐specific signaling molecules, regulators, and effectors, are incorporated into specific signalosomes, where they facilitate and regulate compartmentalization of cyclic nucleotide signaling pathways and specific cellular functions. Currently, only a limited number of PDE inhibitors (PDE3, PDE4, PDE5 inhibitors) are used in clinical practice. Future paths to novel drug discovery include the crystal structure‐based design approach, which has resulted in generation of more effective family‐selective inhibitors, as well as burgeoning development of strategies to alter compartmentalized cyclic nucleotide signaling pathways by selectively targeting individual PDEs and their signalosome partners.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Items 201–261 of 261
Wilson, L. S., Baillie, G. S., Pritchard, L. M., Umana, B., Terrin, A., Zaccolo, M., Houslay, M. D., & Maurice, D. H. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.217026 · Cited by 62 · cited 6×
“In these HAEC, a cell-permeable peptide designed to interfere with Epac1/PDE3B interactions produced effects similar to those elicited by cilostamide (specific PDE3 inhibitor) or siRNA-induced knockdown of PDE3B, that is, Epac1/RRas-dependent activation of PI3Kc (Wilson et al, 2011).”
BackgroundInfluentialSelf-citationPhosphodiesterase-8A binds to and regulates Raf-1 kinase
Brown, K. M., Day, J. P., Huston, E., Zimmermann, B., Hampel, K., Christian, F., Romano, D., Terhzaz, S., Lee, L. C. Y., Willis, M. J., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1303004110 · Cited by 60 · cited 2×
“Binding of AKAP with PKA and PDE8A forms a signaling complex/module or signalosome in which PDE8A interacts with Raf-1 and protects it from inhibitory phosphorylation by PKA (Brown et al, 2013).”
BackgroundNitric oxide: novel therapy for osteoporosis
Wimalawansa, S. J. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560802197162 · Cited by 60
Evaluation of PDE5 and PDE9 Expression in Benign and Malignant Breast Tumors
Karami‐Tehrani, F., Moeinifard, M., Aghaei, M., & Atri, M. (2012) · Archives of Medical Research · doi:10.1016/j.arcmed.2012.08.006 · Cited by 60
Creighton, J. R., Zhu, B., ALEXEYEV, M. F., & Stevens, T. (2007) · Journal of Cell Science · doi:10.1242/jcs.011692 · Cited by 59 · cited 1×
“…PDE4D5, ERK b2AR signaling (Bolger et al, 2006) Myomegalin PDE4D Targeting to Golgi/centrosome (Verde et al, 2001) Spectrin PDE4D4 EC gap formation (Creighton et al, 2008) Ndel1 PDE4D3, PKA Neuronal development (Collins et al, 2008) SHANK PDE4D, CFTR, PKA Membrane ion transport (Lee et al,…”
BackgroundNawrocki, A. R., Rodríguez, C. G., Toolan, D. M., Price, O., Henry, M., Forrest, G., Szeto, D., Keohane, C. A., Pan, Y., Smith, K. M., et al. (2013) · Diabetes · doi:10.2337/db13-0247 · Cited by 59 · cited 7×
“The structure-based design approach was recently used to develop potent and family-selective PDE4 (Card et al, 2005; Burgin et al, 2010), PDE9A (Claffey et al, 2012; Meng et al, 2012), and PDE10A (Malamas et al, 2011; Ho et al, 2012) inhibitors.”
BackgroundInfluentialSafety and efficacy of cilostazol in the management of intermittent claudication
Chi, Y., Lavie, C. J., Milani, R. V., & White, C. J. (2008) · Vascular Health and Risk Management · doi:10.2147/vhrm.s3160 · Cited by 58 · cited 1×
“Cilostazol, a PDE3-selective inhibitor, is widely used to treat intermittent claudication, which is a peripheral vascular disease, characterized by ischemia-induced cramping and pain in the legs (Chi et al, 2008; Liu et al, 2011).”
BackgroundShould bisphosphonates be used for long‐term treatment of glucocorticoid‐induced osteoporosis?
Teitelbaum, S. L., Seton, M., & Saag, K. G. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30135 · Cited by 56 · cited 2×
“PDE inhibitors could play a potential role in the treatment of osteoporosis, especially glucocorticoid-induced osteoporosis in postmenopausal women (Saag, 2003; Teitelbaum et al, 2011).”
BackgroundPalmer, D., Jimmo, S. L., Raymond, D. R., Wilson, L. S., Carter, R. L., & Maurice, D. H. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m606936200 · Cited by 54 · cited 1×
“…(Ahmad et al, 2009) IR PI3K, IRS Insulin/PI3K activation of PDE3B (Rondinone et al, 2000) 14-3-3 PKA, PKB 14-3-3 binding regulates PDE3 activity (Palmer et al, 2007) PI3Kc MAPK, PKB, PKA Inflammation, cardiac contractility (Patrucco et al, 2004; Perino et al, 2011) PI3Kc Epac Angiogenesis, cell…”
BackgroundSelf-citationOger, S., Méhats, C., Dallot, E., CABROL, D., & Leroy, M. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.12.8082 · Cited by 54
Phosphodiesterase Inhibitors: History of Pharmacology
Schudt, C., Hatzelmann, A., Beume, R., & Tenor, H. (2011) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-17969-3_1 · Cited by 54 · cited 1×
“Before they were recognized as PDE inhibitors, however, xanthine derivatives, especially theophylline and caffeine, were used in clinical situations as bronchodilators (acute asthma) and as cardiotonic agents and diuretics (Schudt et al, 2011).”
BackgroundChen, R., Williams, A. J., Liao, Z., Yao, C., Tortella, F. C., & Dave, J. R. (2007) · Neuroscience Letters · doi:10.1016/j.neulet.2007.03.033 · Cited by 53
Nilsson, R., Ahmad, F., Swärd, K., Andersson, U., Weston, M. C., Manganiello, V., & Degerman, E. (2006) · Cellular Signalling · doi:10.1016/j.cellsig.2006.01.010 · Cited by 51 · cited 1×
“…by insulin or a b3AR agonist, CL316,243 (CL), involves the reversible assembly of distinct signalosomes that contain phosphorylated PDE3B and different sets of signaling effectors thought to be involved in activation of PDE3B by insulin or cAMP/PKA (Nilsson et al, 2006; Ahmad et al, 2007, 2009).”
BackgroundSelf-citationAhmad, F., Lindh, R., Tang, Y., Weston, M. C., Degerman, E., & Manganiello, V. C. (2007) · Biochemical Journal · doi:10.1042/bj20060960 · Cited by 50 · cited 2×
“…Submucosal gland secretion (Penmatsa et al, 2010) PDE3B IRS,14-3-3 PI3K, HSP90, PKB Insulin-induced signaling complex, cAMP pools, and lipolysis (Ahmad et al, 2007) 14-3-3, Cav-1 PKA-R, HSP90, Cav-1, PL, PP2A, b3AR b3AR and insulin signaling complexes (Ahmad et al, 2009) IR PI3K, IRS…”
BackgroundSelf-citationAhmad, F., Lindh, R., Tang, Y., Ruishalme, I., Öst, A., Sahachartsiri, B., Strålfors, P., Degerman, E., & Manganiello, V. (2009) · Biochemical Journal · doi:10.1042/bj20090842 · Cited by 50 · cited 2×
“…complex, cAMP pools, and lipolysis (Ahmad et al, 2007) 14-3-3, Cav-1 PKA-R, HSP90, Cav-1, PL, PP2A, b3AR b3AR and insulin signaling complexes (Ahmad et al, 2009) IR PI3K, IRS Insulin/PI3K activation of PDE3B (Rondinone et al, 2000) 14-3-3 PKA, PKB 14-3-3 binding regulates PDE3 activity…”
BackgroundSelf-citationDiminished Phosphodiesterase-8B Potentiates Biphasic Insulin Response to Glucose
Dov, A., Abramovitch, E., Warwar, N., & Nesher, R. (2007) · Endocrinology · doi:10.1210/en.2007-0968 · Cited by 48 · cited 6×
“Altera- tions in expression of PDEs and PDE-gene mutations (especially mutations in PDE6, PDE8B, PDE11A, and PDE4) have been implicated in various diseases and can- cer pathologies.”
BackgroundInfluentialTiwari, S., Dong, H., Kim, E. J., Weintraub, L. R., Epstein, P. M., & Lerner, A. (2004) · Biochemical Pharmacology · doi:10.1016/j.bcp.2004.10.009 · Cited by 47 · cited 1×
“As there is a considerable cross talk between glucocorticoid and cAMP signaling pathways (Tiwari et al, 2005; Lerner and Epstein, 2006), PDE inhibitors, by acting to both promote bone formation and inhibit bone resorption, might fill a critical need as therapeutics for glucocorticoidinduced…”
BackgroundCollins, D. M., Murdoch, H., Dunlop, A. J., Charych, E. I., Baillie, G. S., Wang, Q., Herberg, F. W., Brandon, N. J., Prinz, A., & Houslay, M. D. (2008) · Cellular Signalling · doi:10.1016/j.cellsig.2008.09.017 · Cited by 47 · cited 1×
“…Targeting to Golgi/centrosome (Verde et al, 2001) Spectrin PDE4D4 EC gap formation (Creighton et al, 2008) Ndel1 PDE4D3, PKA Neuronal development (Collins et al, 2008) SHANK PDE4D, CFTR, PKA Membrane ion transport (Lee et al, 2007) PKA,PDE4D, Epac1, VE-Cad VEC permeability and adhesion(Rampersad…”
BackgroundTenor, H., Hatzelmann, A., Beume, R., Lahu, G., Zech, K., & Bethke, T. D. (2011) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-17969-3_3 · Cited by 46 · cited 2×
“In addition to these beneficial effects, however, panPDE4 inhibitors also elicit dose-limiting side effects, especially nausea and emesis, primarily brought about by inhibition of PDE4 [perhaps PDE4D more than other PDE4 subfamilies] (Robichaud et al, 2002) in the brain and gut (Tenor et al, 2011).”
BackgroundSmall Molecule Allosteric Modulators of Phosphodiesterase 4
Gurney, M. E., Burgin, A. B., Magnússon, Ó. Þ., & Stewart, L. J. (2011) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-17969-3_7 · Cited by 46 · cited 2×
“…PDE4B and PDE4D, Burgin and associates have taken advantage of the polymorphisms and generated specific modulators (RS25344, DI59153) for PDE4D with anti-inflammatory, pro-cognitive, and antidepressant actions (without significant emesis) in rodent models (Burgin et al, 2010; Gurney et al, 2011).”
BackgroundPhosphodiesterase 11A (PDE11A) Genetic Variants May Increase Susceptibility to Prostatic Cancer
Faucz, F. R., Horvath, A., Rothenbuhler, A., Almeida, M. Q., Libé, R., Raffin-Sanson, M.-L., Bertherat, J., Carraro, D. M., Soares, F. A., de Campos Molina, G., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1655 · Cited by 46 · cited 1×
“PDE11A mutations may also play a role in susceptibility to prostate cancer (Faucz et al, 2011) and testicular germ cell tumors (TGCT) (Horvath et al, 2009).”
BackgroundPDE5 inhibitors: targeting erectile dysfunction in diabetics
Francis, S. H., & Corbin, J. D. (2011) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2011.08.004 · Cited by 46 · cited 6×
“Male erectile dysfunction is a worldwide public health problem that is often associated with clinically serious comorbidities such as cardiovascular disease, diabetes, atherosclerosis, and metabolic syndrome (Francis and Corbin, 2011).”
BackgroundInfluentialBielekova, B., Richert, N. D., Howard, T., Packer, A. N., Blevins, G., Ohayon, J. M., McFarland, H. F., Stürzebecher, C.-S., & Martinꝉ, R. (2009) · Multiple Sclerosis Journal · doi:10.1177/1352458509345903 · Cited by 45 · cited 1×
“…in patients with multiple sclerosis (MS) was prematurely terminated because of side effects (nausea, emesis) and an unexpected increase in brain inflammation in the MS patients, even though rolipram administration reduced inflammation markers in circulating lymphocytes (Bielekova et al, 2009).”
BackgroundGiembycz, M. A., & Newton, R. (2011) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-17969-3_18 · Cited by 43 · cited 20×
“Conversely, disruptions in these signaling pathways play key roles in the pathogenesis and symptomatic presentations of many clinically relevant disease states, including obesity, diabetes, heart failure, pulmonary hypertension, erectile dysfunction, chronic obstructive pulmonary disease (COPD), arthritis, certain for…”
BackgroundInfluentialCyclic Nucleotide Phosphodiesterase 3 Signaling Complexes
Ahmad, F., Degerman, E., & Manganiello, V. (2012) · Hormone and Metabolic Research · doi:10.1055/s-0032-1312646 · Cited by 42 · cited 1×
“…structural organization, with a conserved catalytic core (250–300 amino acids) in the C-terminal portion of the PDE molecules, which separates divergent N-terminal regulatory regions and targeting domains from hydrophilic C-termini (Bender and Beavo, 2006; Francis et al, 2011; Ahmad et al, 2012).”
BackgroundSelf-citationPDE inhibitors: a new approach to treat metabolic syndrome?
Lugnier, C. (2011) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2011.09.012 · Cited by 42 · cited 2×
“…in Becker and Duchenne muscular dystrophies, heart failure and other cardiovascular disorders, type 2 diabetes, and other disease states (Tsai and Kass, 2009; Francis and Corbin, 2011; Kukreja et al, 2011; Lugnier, 2011; Percival et al, 2011) (cf Clinictrails.gov; and Maurice et al, 2014a).”
BackgroundCYCLIC NUCLEOTIDE PHOSPHODIESTERASE AND CYCLIC AMP*
Thompson, W. J., & Appleman, M. M. (1971) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1971.tb45233.x · Cited by 41 · cited 3×
“, specificities and affinities for cGMP and/or cAMP as well as different sensitivities to available inhibitors and effectors such as calcium/calmodulin), identified five distinct PDEs, now recognized as PDEs1–5 (Thompson and Appleman, 1971; Thompson et al, 1979; Keravis et al, 1980; Yamamoto et al, 1983; Weishaar et a…”
Backgroundβ-cell PDE3B regulates Ca2+-stimulated exocytosis of insulin
Walz, H. A., Wierup, N., Vikman, J., Manganiello, V. C., Degerman, E., Eliasson, L., & Holst, L. S. (2007) · Cellular Signalling · doi:10.1016/j.cellsig.2007.01.030 · Cited by 40 · cited 1×
“For example, cell-based studies (Walz et al, 2007), studies with PDE3B KO mice (Choi et al, 2006), and studies in transgenic mice overexpressing PDE3B in pancreatic b-cells (Harndahl et al, 2002) clearly establish a central role for PDE3B in regulation of insulin secretion.”
BackgroundSelf-citationMuradov, K. G., Granovsky, A. E., & Artemyev, N. O. (2003) · Biochemistry · doi:10.1021/bi027095x · Cited by 38
Phosphodiesterases as Targets for Modulating T-Cell Responses
Bjørgo, E., Moltu, K., & Taskén, K. (2011) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-17969-3_15 · Cited by 38 · cited 1×
“…especially PDE4B, are incorporated, in a PI3K-dependent manner, into a PKB/b-arrestin signalosome and recruited into lipid rafts, where, by modulating compartmentalized cAMP levels, they regulate the cytokine environment important for T-cell activation/differentiation (Bjorgo et al, 2011).”
BackgroundNakao, Y., Koike, T., Ohta, Y., Manaka, T., Imai, Y., & Takaoka, K. (2009) · Bone · doi:10.1016/j.bone.2009.01.370 · Cited by 36
Zhang, W., Ke, H., & Colman, R. W. (2002) · Molecular Pharmacology · doi:10.1124/mol.62.3.514 · Cited by 34 · cited 1×
“It contains a histidine-rich PDE signature sequence motif [HD(X2)H (X4)N] and two consensus metal-binding domains (HX3HX24-26E), which are common to all PDEs and critical for catalytic function (Francis et al, 1994; Zhang et al, 2002).”
BackgroundCyclic nucleotide-based therapeutics for chronic obstructive pulmonary disease
Giembycz, M. A., & Maurice, D. H. (2014) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2014.04.001 · Cited by 34 · cited 2×
“Multiple PDEs can be targeted with multiple drugs, drugs with a single pharmacophore of mixed specificity/selectivity, or drugs with two distinct pharmacophores connected by a chemical linker (Giembycz and Newton, 2011; Giembycz and Maurice, 2014).”
BackgroundSelf-citationPer-Arnt-Sim domain-dependent association of cAMP-phosphodiesterase 8A1 with IκB proteins
Wu, P., & Wang, P. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0407649101 · Cited by 34 · cited 4×
“The N-terminal regulatory region of PDE8 isoforms contains Per-Arnt-Sim domains (PAS domains) [an acronym for three eukaryotic proteins; Period clock protein, aryl hydrocarbon receptor nuclear tranlocator (Arnt), and single-minded protein that contain these sequences] (Wang et al, 2001; Wu and Wang, 2004).”
BackgroundInfluentialKelly, M. P., & Brandon, N. J. (2009) · Progress in brain research · doi:10.1016/s0079-6123(09)17908-6 · Cited by 33 · cited 6×
“In addition to their anti-inflammatory actions and positive effects on cognition and memory enhancement, PDE4 inhibitors have been reported to exhibit neuroprotective or neuroregenerative effects in rodents following ischemia-induced stroke, administration of B-amyloid peptides, or spinal cord injury (Kelly and Brando…”
BackgroundInfluentialHoriuchi, H., Saito, N., Kinoshita, T., Wakabayashi, S., Yotsumoto, N., & Takaoka, K. (2002) · Bone · doi:10.1016/s8756-3282(02)00681-6 · Cited by 31 · cited 2×
“Studies with PDE inhibitors that activate cAMP signaling pathways showed that PDE4-selective inhibitors, rolipram and XT-611 (Horiuchi et al, 2002; Wakabayashi et al, 2002; Yamagami et al, 2003), and the non-specific PDE inhibitor, pentoxifylline (Horiuchi et al, 2004), potentiated bone formation…”
BackgroundPDE3 inhibition in dilated cardiomyopathy
Movsesian, M. A., Wever‐Pinzon, O., & Vandeput, F. (2011) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2011.09.001 · Cited by 31 · cited 2×
“Milrinone is approved, however, for acute treatment of adults awaiting heart transplants and adults with refractory, decompensated heart failure (Movsesian et al, 2011).”
BackgroundGuirguis, E., Hockman, S. C., Chung, Y. W., Ahmad, F., Gavrilova, O., Raghavachari, N., Yang, Y., Niu, G., Chen, X. S., Yu, Z., et al. (2013) · Endocrinology · doi:10.1210/en.2012-2185 · Cited by 31 · cited 1×
“PDE3B KO WAT exhibited phenotypic characteristics of brown adipose tissue (Guirguis et al, 2013).”
BackgroundSelf-citationPercival, J. M., Adamo, C. M., Beavo, J. A., & Froehner, S. C. (2011) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-17969-3_14 · Cited by 30 · cited 1×
“…in Becker and Duchenne muscular dystrophies, heart failure and other cardiovascular disorders, type 2 diabetes, and other disease states (Tsai and Kass, 2009; Francis and Corbin, 2011; Kukreja et al, 2011; Lugnier, 2011; Percival et al, 2011) (cf Clinictrails.gov; and Maurice et al, 2014a).”
BackgroundTargeting phosphodiesterase 3 B enhances cisplatin sensitivity in human cancer cells
Uzawa, K., Kasamatsu, A., Baba, T., Usukura, K., Saito, Y., Sakuma, K., Iyoda, M., Sakamoto, Y., Ogawara, K., Shiiba, M., et al. (2013) · Cancer Medicine · doi:10.1002/cam4.56 · Cited by 30 · cited 1×
“…growth effect of the combination of a PDE3specific inhibitor (cilostazol) and cisplatin was also greater than with either cilostazol or cisplatin, with a significant increase in the number of apoptotic and cell growth-suppressive cancer cells in cisplatin-resistant Sa-R cells (Uzawa et al, 2013).”
BackgroundBroderick, K. E., Zhang, T., Rangaswami, H., Zeng, Y., Zhao, X., Boss, G. R., & Pilz, R. B. (2007) · Molecular Endocrinology · doi:10.1210/me.2005-0389 · Cited by 30 · cited 1×
“…factor alpha1 (Cbfa1)-regulated expression of osteoblast-specific genes such as osteopontin, collagen type I, osteocalcin, and sialoproteins (Rodan and Noda, 1991). cGMP has also been shown to regulate differentiation of osteoblasts (Hagiwara et al, 1996; Broderick et al, 2007; Wimalawansa, 2008).”
BackgroundExpression of phosphodiesterase 6 (PDE6) in human breast cancer cells
Dong, H., Claffey, K. P., Brocke, S., & Epstein, P. M. (2013) · SpringerPlus · doi:10.1186/2193-1801-2-680 · Cited by 29 · cited 1×
“Although expression of PDE6, which specifically hydrolyzes cGMP, was recently reported to be increased in human breast cancer cell lines (Dong et al, 2013), in other human breast cancer cells, inhibition of PDE5, another cGMP-specific PDE, by siRNA-induced PDE5 knockdown or inhibition with the…”
BackgroundTadalafil - a therapeutic option in the management of BPH-LUTS
Carson, C. C., Rosenberg, M. T., Kissel, J., & Wong, D. G. (2013) · International Journal of Clinical Practice · doi:10.1111/ijcp.12305 · Cited by 29 · cited 1×
“The PDE5 inhibitors, avanafil (Stendra:Vivus), a rapidly aching PDE5 inhibitor, and tadalafil (Cialis), have recently been approved for the treatment of erectile dysfunction and BPH, respectively (Carson et al, 2014; Wang et al, 2014).”
BackgroundRole of phosphodiesterase 2 in growth and invasion of human malignant melanoma cells
Hiramoto, K., Murata, T., Shimizu, K., Morita, H., Inui, M., Manganiello, V. C., Tagawa, T., & Arai, N. (2014) · Cellular Signalling · doi:10.1016/j.cellsig.2014.03.031 · Cited by 27 · cited 1×
“PDE2A regulates cell cycle progression in human oral malignant melanoma PMP cells by modulating cyclin A expression (Morita et al, 2013); targeting PDE2A by the PDE2 inhibitor, EHNA, or siRNA-induced knockdown inhibited PMP cell proliferation and invasion (Hiramoto et al, 2014).”
BackgroundSelf-citationZhang, X., Cahill, K. B., Elfenbein, A., Arshavsky, V. Y., & Cote, R. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m803948200 · Cited by 26 · cited 7×
“Cyclic nucleotide binding to GAF domains in PDEs 2, 5, and 6 allosterically activates their catalytic activities (Francis et al, 2002; Wu et al, 2004; Zhang et al, 2008b).”
BackgroundInfluentialWang, H., Yuan, J.-Q., Hu, X., Tao, K., Liu, J., & Hu, D. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.909391 · Cited by 25 · cited 1×
“The PDE5 inhibitors, avanafil (Stendra:Vivus), a rapidly aching PDE5 inhibitor, and tadalafil (Cialis), have recently been approved for the treatment of erectile dysfunction and BPH, respectively (Carson et al, 2014; Wang et al, 2014).”
BackgroundGiembycz, M. A., & Newton, R. (2013) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2013.09.007 · Cited by 25 · cited 1×
“…to reduce exacerbations in subsets of COPD patients with bronchitis, and as an add-on therapy to patients receiving inhaled corticosteroids, or standard bronchodilators such as longacting b2AR agonists (LABA) or anticholinergic drugs (Fabbri et al, 2009; Rabe, 2011; Giembycz and Newton, 2014).”
BackgroundPhosphodiesterases as Targets for Intermittent Claudication
Liu, Y., Shakur, Y., & Kambayashi, J. (2011) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-17969-3_9 · Cited by 22 · cited 2×
“Cilostazol, a PDE3-selective inhibitor, is widely used to treat intermittent claudication, which is a peripheral vascular disease, characterized by ischemia-induced cramping and pain in the legs (Chi et al, 2008; Liu et al, 2011).”
BackgroundKita, T., Fujimura, M., Myou, S., Watanabe, K., Waseda, Y., & Nakao, S. (2009) · Allergology International · doi:10.2332/allergolint.08-oa-0053 · Cited by 22 · cited 1×
“PDE1 inhibitors block smooth muscle proliferation, and the dual PDE1/PDE4 inhibitor, KF 1954, was reported to reduce both remolding and inflammation in an asthma murine model (Kita et al, 2009).”
BackgroundNew drug therapies for multiple sclerosis
Mangas, A., Coveñas, R., & Geffard, M. (2010) · Current Opinion in Neurology · doi:10.1097/wco.0b013e32833960f6 · Cited by 20
Management of Benign Prostatic Hyperplasia: Role of Phosphodiesterase-5 Inhibitors
Gacci, M., Carini, M., Salvi, M., Sebastianelli, A., Vignozzi, L., Corona, G., Maggi, M., McVary, K. T., Kaplan, S. A., Oelke, M., et al. (2014) · Drugs & Aging · doi:10.1007/s40266-014-0177-1 · Cited by 18
Critical role for PDE4 subfamilies in the development of experimental autoimmune encephalomyelitis
Sanabra, C., Johansson, E. M., & Mengod, G. (2012) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2012.12.005 · Cited by 17 · cited 1×
“Although expression of PDE4B2 is increased in the brainstem and spinal cord in mice with EAE, and the PDE4 inhibitor, rolipram, reduced clinical signs of the disease, PDE4B KO mice unexpectedly developed EAE faster than WT mice (Sanabra et al, 2013).”
BackgroundYamagami, H., Nishioka, T., Ochiai, E., Fukushima, K., Nomura, M., Kasugai, S., Moritani, S., Yokogawa, K., & Miyamoto, K. (2003) · Biochemical Pharmacology · doi:10.1016/s0006-2952(03)00409-x · Cited by 16 · cited 1×
“…that activate cAMP signaling pathways showed that PDE4-selective inhibitors, rolipram and XT-611 (Horiuchi et al, 2002; Wakabayashi et al, 2002; Yamagami et al, 2003), and the non-specific PDE inhibitor, pentoxifylline (Horiuchi et al, 2004), potentiated bone formation by BMP-stimulated…”
BackgroundTokuhara, Y., Wakitani, S., Imai, Y., Nomura, C., Hoshino, M., Yano, K., Taguchi, S., Kim, M., Kadoya, Y., & Takaoka, K. (2009) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-009-0103-5 · Cited by 15 · cited 1×
“…that PDE inhibitors promote bone formation via stimulation of osteoblast differentia- tion/formation (Kinoshita et al, 2000; Wakabayashi et al, 2002; Tokuhara et al, 2010) and/or inhibition of bone resorption (Park and Yim, 2007; Yao et al, 2007; Noh et al, 2009), and thus could possibly provide…”
BackgroundAghaloo, T. L., Pirih, F. Q. M., Shi, A., Bezouglaia, O., & Tetradis, S. (2006) · Journal of Periodontology · doi:10.1902/jop.2006.77.1.21 · Cited by 14 · cited 1×
“PTH and its active N-terminal peptide, which acts through PTH receptor 1 (PTHR1), signal via cAMP/PKA and Ca2+/PKC pathways (Aghaloo et al, 2006; Datta and Abou-Samra, 2009; Nakao et al, 2009).”
BackgroundLabuda, M., Laberge, S., Brière, J., Bérubé, D., Beaulieu, P., Pastinen, T., & Krajinović, M. (2011) · Mediators of Inflammation · doi:10.1155/2011/301695 · Cited by 12 · cited 1×
“…polymorphisms (SNPs) have been correlated with ischemic stroke (Gretarsdottir et al, 2003) and with responses to short-acting bronchodilators in pediatric asthma (Labuda et al, 2011), whereas PDE4B SNPs and decreased expression of PDE4B are associated with schizophrenia (Fatemi et al, 2008).”
BackgroundMaurice, D. H., Wilson, L. S., Rampersad, S. N., Hubert, F., Truong, T. K., Kaczmarek, M., Brzezinska, P. B., Freitag, S. I., Umana, M. B., & Wudwud, A. (2014) · Biochemical Society Transactions · doi:10.1042/bst20130268 · Cited by 11 · cited 15×
“…AKAPs, and/or other scaffold proteins (Table 2 represents a partial list of PDE-containing signalosomes, with scaffold proteins, known interacting partners, and presumed function) (Houslay et al, 2007; Tsai and Kass, 2009; Keravis and Lugnier, 2010; Francis et al, 2011; Maurice et al, 2014a,b).”
BackgroundInfluentialSelf-citationEmerging therapies for rheumatoid arthritis
Jacques, P., & den Bosch, F. E. V. (2013) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2013.807339 · Cited by 11
Bone and the cAMP Signaling Pathway: Emerging Therapeutics
Epstein, P. M. (2012) · Springer eBooks · doi:10.1007/978-1-4471-2745-1_16 · Cited by 7 · cited 3×
“…of bone resorption (Park and Yim, 2007; Yao et al, 2007; Noh et al, 2009), and thus could possibly provide novel therapeutics for osteoporosis (Epstein, 2012). cAMP and cGMP have dramatic effects on osteoblasts. cAMP derivatives or cAMP-generating agents such as PTH and forskolin inhibit…”
BackgroundYoshida, H., Ashikawa, Y., Itoh, S., Nakagawa, T., ASANUMA, A., Tanabe, S., Inoue, Y. H., & Hidaka, H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0046432 · Cited by 7
Satoh, K., Guo, M., & Sairenji, N. (2009) · Journal of Oral Science · doi:10.2334/josnusd.51.173 · Cited by 5 · cited 1×
“…constitutive amylase release, was enhanced in the presence of a PDE4-specific inhibitor (rolipram) in mouse, rat, and rabbit parotid acinar cells (Satoh et al, 2009), and a PDE3-specific inhibitor (cilostamide) increased apomucin gene expression in isolated rat submandibular acini cells (Shimizu…”
Background
Cited by
Therapeutic targeting of 3′,5′-cyclic nucleotide phosphodiesterases: inhibition and beyond
Baillie, G. S., Tejeda, G. S., & Kelly, M. P. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0033-4 · Cited by 339
Targeting cell signaling in allergic asthma
Athari, S. S. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0079-0 · Cited by 312
Nitric oxide/cGMP/CREB pathway and amyloid-beta crosstalk: From physiology to Alzheimer’s disease
Tropea, M. R., Gulisano, W., Vacanti, V., Arancio, O., Puzzo, D., & Palmeri, A. (2022) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2022.11.022 · Cited by 55
Metadata
- Authors
- Ahmad, F., Murata, T., Shimizu, K., Degerman, E., Maurice, D., & Manganiello, V
- Venue
- Oral Diseases
- Publisher
- Wiley
- Published
- 2014-09-12
- Volume
- 21
- Issue
- 1
- Pages
- e25-50
- ISSN
- 1354-523X (ISSN-L)
- 1601-0825
- OpenAlex
- W2049374415
- Cited by
- 184
- References
- 261
- FWCI
- 3.16
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.